Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 10/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175182 | 0.85 | CYP2A6 (0.56) | CYP2A6CYP2C9CYP2E1CYP3A4CYP2D6 | |
| SCHEMBL21409023 | 0.77 | CYP2A6 (0.44) | CYP2A6CYP2C9CYP3A4CCNT1CDK9 | |
| SCHEMBL21409025 | 0.77 | CYP2A6 (0.44) | CYP2A6CYP2C9CYP3A4CCNT1CDK9 | |
| SCHEMBL9956377 | 0.72 | CYP2A6 (1.00) | CYP2A6 | |
| SCHEMBL91009 | 0.72 | CYP2A6 (1.00) | CYP2A6 | |
| SCHEMBL29502957 | 0.72 | CYP2A6 (1.00) | CYP2A6 | |
| SCHEMBL22791609 | 0.71 | NAMPT (0.38) | CYP2A6CYP2C9NAMPT | |
| SCHEMBL16901677 | 0.71 | NAMPT (0.40) | CYP2A6CYP2C9NAMPT | |
| SCHEMBL18660625 | 0.71 | HASPIN (0.35) | CYP2A6CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2629271 | 0.71 | MAPT (0.51) | CYP2A6CYP2C9CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| WO-2013127269-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | GENENTECH,INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-8193359-B2 | G-protein coupled receptor agonists | PROSIDION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1838706-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006067532-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LTD (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1406901-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-4847264-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | CYP2A6 139/4885CYP2C9 112/4885CYP2E1 290/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | CYP2A6 624/4885CYP2C9 177/4885CYP2E1 655/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | CYP2A6 624/4885CYP2C9 177/4885CYP2E1 655/4885 |
| US-20090099227-A1 | G-Protein Coupled Receptor Agonists | GPR119, GPR65, GPR84 | CYP2A6 770/4885CYP2C9 1280/4885CYP2E1 677/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CYP2A6 1646/4885CYP2C9 2180/4885CYP2E1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.